Stuart Madden, chief scientific officer at neuroscience company Neurelis, examines the drug delivery sector and the opportunities non-invasive methods present to the industry and patients.
Non-invasive drug delivery is a broad term typically referring to routes other than parenteral administration, such as oral, intranasal, buccal/sublingual, pulmonary, and transdermal routes. For pharmaceutical leaders and decision-makers on the manufacturing side of the industry, it’s important to understand available delivery methods, their unique benefits and use cases and innovations which are making some methods attractive solutions for boosting available therapeutics.
Pros and Cons of Parenteral Administration